Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July

 
• By Sten Stovall
  
Carcinoma
Filings to be based on Positive top line results from Phase III NALA trial • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category